Clinical Trials
27 trialsNCT05362773 2026-05-22
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Phase 1 Recruiting
NCT06708897 2025-12-05
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
Lomond Therapeutics Holdings, Inc.
Phase 1 Recruiting
NCT06787131 2025-12-05
Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
Lomond Therapeutics Holdings, Inc.
Phase 1 Completed
NCT00788684 2025-02-20
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
AbbVie
Phase 1 Completed
NCT02920697 2024-07-25
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
Servier
Phase 1 Completed
NCT00457782 2024-04-25
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT06209671 2024-01-17
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Unknown
NCT03833180 2024-01-12
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Completed
NCT04763083 2023-07-07
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
NovalGen Ltd.
Phase 1 Unknown
NCT05487651 2023-05-18
ANCHOR2
Athenex, Inc.
Phase 1 Unknown
NCT00772486 2021-09-22
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
Memgen, Inc.
Phase 1 Completed
NCT01976520 2021-04-08
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
XEME Biopharma Inc.
Phase 1 Unknown
NCT01659255 2021-03-16
Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL
Gilead Sciences
Phase 1 Completed
NCT01732861 2019-12-20
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
Celgene
Phase 1 Completed
NCT00419250 2019-11-08
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
Celgene
Phase 1 Completed
NCT02848911 2019-06-19
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
Affimed GmbH
Phase 1 Terminated
NCT00697346 2019-05-31
Study of MLN8237 in Participants With Advanced Hematological Malignancies
Takeda
Phase 1 Completed
NCT03383952 2017-12-27
A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
Immune Cell, Inc.
Phase 1 Unknown
NCT01110031 2017-11-13
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects
GlaxoSmithKline
Phase 1 Completed
NCT01744626 2016-04-19
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Celgene Corporation
Phase 1 Completed
NCT02556346 2016-03-02
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Molecular Templates, Inc.
Phase 1 Withdrawn
NCT00871663 2015-04-20
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01292135 2014-07-24
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Pharmacyclics LLC.
Phase 1 Completed
NCT01955668 2014-06-19
AZD6738 First Time in Patient Multiple Ascending Dose Study
AstraZeneca
Phase 1 Completed
NCT00849654 2013-05-22
PCYC-04753
Pharmacyclics LLC.
Phase 1 Completed
NCT00783588 2008-10-31
A Phase I Extension Trial of Repeated Infusions of ISF35
Memgen, Inc.
Phase 1 Completed
NCT00779883 2008-10-24
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
Memgen, Inc.
Phase 1 Completed